Regeneron’s gene therapy is being tested in a clinical trial.
The Regeneron Pharmaceuticals company logo on a building at the company's Westchester campus in Tarrytown, New York state, on Sept. 17, 2020. Brendan McDermid/Reuters
An experimental gene therapy gave a deaf child the ability to hear, her family and investigators for a clinical trial say.
Opal Sandy, the girl, received an injection of DB-OTO, Regeneron’s gene therapy, in her ear when she was 11 months old. Her hearing was assessed as normal within six months.
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
